STOCKS & COMMODITIES magazine. The Traders' Magazine

Register or Log In — Traders.com and STOCKS & COMMODITIES magazine

TECHNICAL ANALYSIS  |  April 19, 2018
ABBV'S Band of Resistance
AbbVie's (ABBV) stock got slammed after disappointing results on small cell lung cancer drug, Rova-T, test results. The drug was the lead product of Stemcentrix, the biotech company ABBV acquired back in 2016 for $5.8 billion. On Thursday, March 22, 2018, ABBV'S stock gapped down and lost 12.8% of its value in heavy trading. The gap down resulted in a band of resistance which is the subject of this article.
by Stella Osoba, CMT

Technical Analysis of STOCKS & COMMODITIES
The Traders’ Magazine since 1982
has had over 1,226,237 subscribers from 174 different countries.
37,000 Page Traders’ Archive for $89.99

NOT A SUBSCRIBER?

To continue reading, sign-up for trial access to Traders.com and the S&C Archive37,000 pages of trading ideas!




After verifying your email address, you will have limited access to the S&C Archive, as well as access to a Digital Edition of S&C, and access to Traders.com Advantage and Working Money for 30 days.



DEPARTMENTS: Advertising | Editorial | Circulation | Contact Us | BY PHONE: (206) 938-0570

PTSK — The Professional Traders' Starter Kit
Home — S&C Magazine | Working Money Magazine | Traders.com Advantage | Online Store | Traders’ Resource
Add a Product to Traders’ Resource | Message Boards | Subscribe/Renew | Free Trial Issue | Article Code | Search

Copyright © 1982–2018 Technical Analysis, Inc. All rights reserved. Read our disclaimer & privacy statement.